COMMUNIQUÉS West-GlobeNewswire

Progyny Appoints Healthcare Veteran Debra Morris to Board of Directors
16/01/2025
NEW YORK, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a transformative fertility, family building and women’s health benefits solution, today announced the appointment of 30-year healthcare industry [...]
Autoimmunity BioSolutions to Present at the 2025 Sequire Investor Summit in Puerto Rico
16/01/2025
Houston, Texas, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Autoimmunity BioSolutions is proud to announce that it will be presenting at the upcoming Sequire Investor Summit 2025. The 2025 Edition of the Sequire Investor Summit [...]
PeopleOne Health Appoints Ty Arlint as Chief Revenue Officer
16/01/2025
Seasoned healthcare executive to spearhead growth strategies and market expansion as PeopleOne Health brings its innovative value-based care model to more regions PITTSBURGH, Jan. 16, 2025 (GLOBE NEWSWIRE) -- PeopleOne [...]
Metagenomi Highlights Progress Across Therapeutic Portfolio and Outlines Anticipated Milestones
16/01/2025
MGX-001 in Hemophilia A Advances Towards US and Ex-US Regulatory Interactions in 2025 NHP Proof-of-Concept Anticipated for Secreted Protein Deficiency Platform in 2025 Leveraging MGX-001 Editing Approach On Track for [...]
Femasys Announces Notice of Allowance for New U.S. Patent Application Covering Use of FemaSeed® for Female Infertility Treatment
16/01/2025
FemaSeed ® patent application provides additional coverage for Femasys’ therapeutic option for women seeking infertility solution ATLANTA, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading [...]
FOXO TECHNOLOGIES INC., CONFIRMS DETAILS OF SPECIAL MEETING OF SHAREHOLDERS ON JANUARY 17, 2025.
16/01/2025
MINNEAPOLIS, MN, Jan. 16, 2025 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (the “Company” or “FOXO”), will hold its previously announced Special Meeting of its Shareholders at 10:30 am EST on Friday [...]
United Arab Emirates Ministry of Health and Prevention Approves Biomerica’s Fortel® PSA Screening Test to Detect an Early Sign of Prostate Cancer
16/01/2025
- 10-Minute PSA Test for Early Detection of Prostate Specific Antigen (PSA), an Early Warning Sign of Prostate Cancer - Prostate Cancer: The Second Most Common Cancer in Men Globally IRVINE, Calif., Jan. 16, 2025 (GLOBE [...]
Carmell Announces Closing of Elevai Skincare Acquisition
16/01/2025
PITTSBURGH, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Carmell Corporation (Nasdaq: CTCX), a bio-aesthetics company focused on skin and hair health (“Carmell”, the “Company”, “we”, “our”, or “us”), today announced the closing of [...]
Enrollment Starts in Africa CDC-Led MpOx Therapeutic Study (MOSA)
16/01/2025
ADDIS ABABA, Ethiopia and KINSHASA, Democratic Republic of the Congo and WASHINGTON and PARIS, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Africa CDC’s support for the MOSA, a pan-African randomized platform adaptive trial for [...]
Nusano and Atley Solutions in Collaboration to Accelerate Astatine-211 Development
16/01/2025
Nusano isotope production to deliver breakthrough, 100X increase in global At-211 supply, and Atley’s radiopharmaceutical manufacturing technology to enable scalable At-211 radiopharmaceutical supply VALENCIA, Calif. [...]
Predictive Oncology Announces Planned European Launch of its ChemoFx® Treatment Selection Marker and Tumor Profiling Assay
16/01/2025
Initial plans target European clinical trials while providing standard testing to clinicians for individual patients There are an estimated 250,000 gynecologic cancers diagnosed annually across Europe PITTSBURGH, Jan. [...]
Inteleos Foundation Announces 2025 MedMissions Award to Advance Ultrasound Access in Four Nations
16/01/2025
ROCKVILLE, Md., Jan. 16, 2025 (GLOBE NEWSWIRE) -- The Inteleos Foundation, a global health nonprofit organization, has announced the selection of three recipients of the annual MedMissions Award, designed to advance [...]
Palisade Bio Completes All Five SAD Cohorts and Advances to MAD Cohorts of Phase 1a/b Study of PALI-2108 for Treatment of Ulcerative Colitis
16/01/2025
Company on track to report topline data in first half of 2025 Positive preliminary data from all five single ascending dose (SAD) cohorts ranging from 15mg to 450mg support safety and tolerability of PALI-2108 Continued [...]
NOTICE TO DISREGARD -- King Faisal Specialist Hospital & Research Centre
16/01/2025
RIYADH, Saudia Arabia, Jan. 16, 2025 (GLOBE NEWSWIRE) -- We are advised by King Faisal Specialist Hospital & Research Centre that journalists and other readers should disregard the news release, “KFSH&RC [...]
Samsung Bioepis Releases First Quarter 2025 US Biosimilar Market Report
16/01/2025
Marks the Third Year Since the Launch of the First US Biosimilar Market Report INCHEON, South Korea, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. today released its First Quarter 2025 Biosimilar Market [...]
Ocugen, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of OCU200—a Novel Integrin-Targeting Biologic for Diabetic Macular Edema
16/01/2025
MALVERN, Pa., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, [...]
Avicanna Announces Scientific and Medical Affairs Collaboration with Vectura Fertin Pharma
16/01/2025
Collaboration aims to facilitate research and medical affairs initiatives related to medical cannabis in Canada TORONTO, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. (“ Avicanna ” or the “ Company ”) (TSX: AVCN) ( [...]
The Joint Corp. Reports 2024 Operating Metrics
16/01/2025
- Adjustments Performed in 2024 Grows 9%, Compared to 2023 - - Receives Letters of Intent for the majority of the Corporate Portfolio in Early January 2025 - SCOTTSDALE, Ariz., Jan. 16, 2025 (GLOBE NEWSWIRE) -- The [...]
Avacta Announces Positive New Data from the AVA6000 Phase 1 trial Demonstrating Clinically Meaningful Tumor Shrinkage in Patients with Salivary Gland Cancers
16/01/2025
Meaningful tumor shrinkage observed in five out of 10 patients with partial and minor responses and 90% disease control rate in patients with salivary gland cancers Phase 1b expansion cohorts screening patients in [...]

Pages